This review has deliberately distinguished failed biology from failed pharmacology, emphasizing that genuine on-target toxicity, repeated lack of efficacy in well-designed human studies, or insurmountable technical barriers justify abandonment
This counterintuitive response resolves with dose reduction
Last week, the central government passed changes to the Drugs Rules, 1945, to add cell- or stem cell-derived products, gene therapeutic products, and xenografts to the list of treatments under the joint supervision of central and state regulators
Future Directions: Cagrilintide in 2026 and Beyond The landscape of cagrilintide research and clinical application continues to evolve rapidly as we progress through 2026
Available at: (Accessed March 27, 2020)